For people with liver cancer, taking vitamin K alongside their usual treatment is linked to a lower chance of the cancer getting worse. The numbers show that patients taking vitamin K had a 38% lower risk of the disease advancing compared to those not taking it.
See the scientific wording
In patients with hepatocellular carcinoma, adding vitamin K to standard treatment is associated with a significantly lower risk of disease progression (hazard ratio 0.62, 95% CI 0.47–0.82), indicating a potential benefit in delaying tumor advancement.
Very strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
The study found that people with liver cancer who took vitamin K had slower cancer growth, just as the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Vitamin K2 slows down liver cancer by doing two things. First, it stops cancer cells from growing and multiplying by blocking certain signals that tell them to divide. Second, it cuts off the blood supply that the tumor needs to feed on by blocking a key protein that helps new blood vessels form. With less growth and less food, the cancer grows slower and the disease takes longer to get worse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
For people with liver cancer, taking vitamin K alongside their usual treatment is linked to a lower chance of the cancer getting worse. The numbers show that patients taking vitamin K had a 38% lower risk of the disease advancing compared to those not taking it.
Mechanism
1 studyVitamin K2 works in two ways to slow down liver cancer. It stops cancer cells from dividing and it prevents the tumor from building new blood vessels to get food. This combination makes the cancer grow slower, so the disease doesn't progress as fast.
Vitamin K2 slows down liver cancer by doing two things. First, it stops cancer cells from growing and multiplying by blocking certain signals that tell them to divide. Second, it cuts off the blood supply that the tumor needs to feed on by blocking a key protein that helps new blood vessels form. With less growth and less food, the cancer grows slower and the disease takes longer to get worse.
VK2 enters hepatocellular carcinoma cells and inhibits IKK kinase activity.
Inhibition of IKK prevents IκB phosphorylation, thereby blocking NF-κB activation.
Suppressed NF-κB leads to reduced cyclin D1 expression, slowing cell cycle progression.
VK2 also inhibits PKC and PKD1, activating the PKA/p53 pathway, which promotes p21 transcription, inducing cell cycle arrest.
Additionally, VK2 downregulates the expression of HCC-derived growth factor, reducing autocrine growth stimulation.
In parallel, VK2 selectively inhibits VEGFR2 phosphorylation on tumor endothelial cells, blocking downstream angiogenic signaling.
This inhibition prevents the post-TACE angiogenesis rebound, reducing tumor vascularization and nutrient supply.
The combined anti-proliferative and anti-angiogenic effects result in delayed tumor progression and improved progression-free survival.
Evidence from Studies
Supporting (1)
Community contributions welcome
The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis
The study found that people with liver cancer who took vitamin K had slower cancer growth, just as the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials of Vitamin K Supplementation in Hepatocellular Carcinoma
A systematic review and meta-analysis of all randomized controlled trials comparing standard treatment plus vitamin K versus standard treatment alone in patients with hepatocellular carcinoma, with outcomes including time to disease progression, progression-free survival, and overall survival, searched across major databases without language restrictions.
Randomized Controlled Trial of Vitamin K Added to Standard Treatment vs Standard Treatment Alone in Hepatocellular Carcinoma
A phase III, double-blind, placebo-controlled randomized trial enrolling patients with histologically confirmed hepatocellular carcinoma, randomized to receive either standard treatment plus vitamin K (e.g., 30 mg/day oral phytonadione) or standard treatment plus placebo, for at least 12 months, with time to disease progression as the primary outcome measured by RECIST criteria and assessed at regular intervals.
Prospective Cohort Study on Vitamin K Use and Disease Progression in Hepatocellular Carcinoma Patients
A prospective cohort study following a large, well-characterized cohort of patients with hepatocellular carcinoma, recording vitamin K supplement use (dose, duration, adherence) and standard treatments at baseline, and following them for at least 2 years to assess time to disease progression, adjusting for known confounders such as age, tumor stage, liver function, and concurrent treatments.
Case-Control Study of Vitamin K Exposure and Disease Progression in Hepatocellular Carcinoma
A case-control study within a large healthcare database: cases are HCC patients with documented disease progression, controls are HCC patients without progression (matched on age, sex, tumor stage, and treatment), and vitamin K supplement use is compared between groups using medical records or patient interviews.